Argus raised the firm’s price target on Boston Scientific (BSX) to $130 from $105 and keeps a Buy rating on the shares. The firm sees strong growth opportunities for Boston Scientific in innovative medtech therapies, supported by recently launched products and M&A and also contends that its Farapulse and Watchman products are “strong drivers of sales growth”, the analyst tells investors in a research note. Boston Scientific is also gaining share in Cardiology and expanding its presence in overseas markets, such as Japan, China and Europe, Argus adds.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BSX:
- Optimistic 2025 Outlook and Strong Innovation Drive Buy Rating for Boston Scientific
- Boston Scientific price target raised to $120 from $115 at Stifel
- Boston Scientific price target raised to $118 from $111 at Barclays
- Boston Scientific price target raised to $122 from $119 at Raymond James
- Boston Scientific price target raised to $120 from $110 at Truist
Questions or Comments about the article? Write to editor@tipranks.com